Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022
- PMID: 38608936
- DOI: 10.1016/j.jgar.2024.03.020
Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022
Abstract
Objectives: To report trends in carbapenem resistance and difficult-to-treat resistance (DTR) among clinical isolates of Gram-negative priority pathogens collected by the ATLAS global surveillance program from 2018 to 2022.
Methods: Reference broth microdilution testing was performed in a central laboratory for 79,214 Enterobacterales, 30,504 Pseudomonas aeruginosa, and 13,500 Acinetobacter baumannii-calcoaceticus complex isolates collected by a constant set of 157 medical centres in 49 countries in Asia Pacific (APAC), Europe (EUR), Latin America (LATAM), Middle East-Africa (MEA), and North America (NA) regions. MICs were interpreted by 2023 CLSI M100 breakpoints. β-lactamase genes were identified for meropenem-nonsusceptible (MIC ≥2 mg/L) Enterobacterales isolates.
Results: Carbapenem-resistant Enterobacterales (CRE) detection increased (P < 0.05) in APAC, EUR, LATAM, and MEA regions and decreased in NA, while annual DTR percentages increased in all five regions. Carbapenem-resistant P. aeruginosa (CRPA; decreased in MEA region) and carbapenem-resistant A. baumannii-calcoaceticus complex (CRAB; decreased in MEA region and increased in EUR) remained relatively stable over time in all regions, although notably, annual percentages of CRAB and DTR A. baumannii-calcoaceticus complex isolates were consistently >25 percentage points lower in NA than in other regions. For all regions except NA, the majority of changes in CRE percentages could be attributed to hospital-acquired infections. Among meropenem-nonsusceptible Enterobacterales, KPC was the most frequent carbapenemase in NA and EUR each year. NDM was the most prevalent carbapenemase detected in 2022 in other global regions.
Conclusion: CRE, CRPA, CRAB, and DTR rates vary among global regions over time highlighting the need for continuing surveillance to inform treatment strategies and antimicrobial stewardship.
Keywords: Acinetobacter baumannii-calcoaceticus complex; Carbapenem resistance; Difficult-to-treat resistance; Enterobacterales; Pseudomonas aeruginosa; Surveillance.
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals.Microbiol Spectr. 2024 Nov 5;12(11):e0147424. doi: 10.1128/spectrum.01474-24. Epub 2024 Oct 10. Microbiol Spectr. 2024. PMID: 39387599 Free PMC article.
-
In Vitro Activity of New β-Lactam-β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019.Microbiol Spectr. 2022 Aug 31;10(4):e0185422. doi: 10.1128/spectrum.01854-22. Epub 2022 Jul 12. Microbiol Spectr. 2022. PMID: 35862963 Free PMC article.
-
Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017.Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0200020. doi: 10.1128/AAC.02000-20. Epub 2021 Jun 17. Antimicrob Agents Chemother. 2021. PMID: 33972241 Free PMC article.
-
Control of Carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in Healthcare Facilities: A Systematic Review and Reanalysis of Quasi-experimental Studies.Clin Infect Dis. 2019 Feb 15;68(5):873-884. doi: 10.1093/cid/ciy752. Clin Infect Dis. 2019. PMID: 30475989 Free PMC article.
-
A systematic review and meta-analysis: rising prevalence of colistin resistance in ICU-acquired Gram-negative bacteria.APMIS. 2025 Jan;133(1):e13508. doi: 10.1111/apm.13508. APMIS. 2025. PMID: 39710513
Cited by
-
National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study.Antibiotics (Basel). 2024 Nov 27;13(12):1139. doi: 10.3390/antibiotics13121139. Antibiotics (Basel). 2024. PMID: 39766529 Free PMC article.
-
Incidence and risk factors of resistant Pseudomonas aeruginosa infections: a multicenter study in Lebanese tertiary hospitals.BMC Infect Dis. 2025 Aug 20;25(1):1048. doi: 10.1186/s12879-025-11467-4. BMC Infect Dis. 2025. PMID: 40836228 No abstract available.
-
Antimicrobial resistance and virulence in Klebsiella pneumoniae: a four-month study in Osogbo, Nigeria.Antimicrob Steward Healthc Epidemiol. 2025 Feb 25;5(1):e64. doi: 10.1017/ash.2025.21. eCollection 2025. Antimicrob Steward Healthc Epidemiol. 2025. PMID: 40026760 Free PMC article.
-
Investigating the Antimicrobial Potential of 560 Compounds from the Pandemic Response Box and COVID Box against Resistant Gram-Negative Bacteria.Antibiotics (Basel). 2024 Aug 1;13(8):723. doi: 10.3390/antibiotics13080723. Antibiotics (Basel). 2024. PMID: 39200023 Free PMC article.
-
Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective.Infection. 2024 Aug;52(4):1235-1268. doi: 10.1007/s15010-024-02313-x. Epub 2024 Jul 2. Infection. 2024. PMID: 38954392 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical